Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab after chemoradiotherapy versus chemoradiotherapy alone in limited-stage small-cell lung cancer
NL-OMON60413Phase 2Active, not recruiting
- Sponsor
- Norwegian University of Science and Technology
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by Norwegian University of Science and Technology. Primary endpoint: Overall survival. Started Jun 2020; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON60413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60413.